Immunoprecipitation. Cell lines were labeled metabolically for 12 h with [sSS]methionine (Amersham Corp., Arlington Heights, IL). 10 million cells from each line were labeled with 1 mCi of radionuclide. Cell lysates were prepared as described (14) . For immunoprecipitation, we complexed monoclonal antibodies to protein A-Sepharose and used this complex to immunoprecipitate the cell lysates. Normal mouse sera was used as a negative control for each lysate. The precipitates were displayed by electrophoresis on 7-14% polyacrylamide gradient gels as described (15) . Gels were treated with Enhance (New England Nuclear, Boston, MA) before exposure to Kodak XRP films (Eastman Kodak Co., Rochester, NY). The film was exposed using intensifying screens at -70°C for 48 h.
Preparation and Hybridization of Lung Cancer Cell Line DNAs and
RNAs. Cells were grown as described above. DNA was prepared from each cell line and 15 ~g was digested with EcoRI, electrophoresed on a 0.8% agarose gel, denatured, and transferred to nitrocellulose (16) . Hybridization was performed using 50% dextran sulfate (17) with the s2p-labeled probe and washing at 52°C (18) . The HLA probe used was the human cDNA plasmid, psw, obtained from Dr. Sherman Weissman (19) . The B2m probe used was a human cDNA plasmid obtained from Dr. R. Bruce Wallace (20) .
A postnuclear supernatent prepared from fresh cell cultures (21) was phenol/chloroform extracted and ethanol precipitated. 10 #g of total cytoplasmic RNA was denatured and electrophoresed on a 1% agarose-formaldebyde gel (22) , that had been modified by using 0.22 M formaldehyde in the gel and electrophoresing at 160 V for 4 h. The gel was soaked in 3 M NaCI, 0.3 M sodium citrate. Transfer, hybridization, and washing were essentially as described for DNA.
Interferon Induction of HLA-frame and 13~rn Proteins. Human recombinant leukocyte A
interferon was supplied by Hoffmann-La Roche, Inc., Nutley, NJ. Its titer was 3 × 106 reference units per milliliter, and its specific activity was 6 × 105 reference units per milligram of protein. Human gamma interferon (Meloy Laboratories, Springfield, VA) had a titer of 1 x 106 reference units per milliliter and a specific activity of 1 × 106 reference units per milligram of protein. Seven SCLC lines, five NSCLC lines, and one B lymphoblastoid line were grown in microtiter dishes at 105 cells per well. Gamma interferon was added to triplicate wells of each line at concentrations of 0-104 U/ml. After 48 h, cells were washed three times in PBS, transferred to polyvinylchloride plates (Dynatech Laboratories, Inc., Alexandria, VA) and fixed with 0.25% glutaraldehyde. The plates were washed twice with PBS and blocked with 1% BSA. Each line was assayed at each interferon concentration with 10 t~g/ml monoclonal antibodies W6/32, L-368, and (Becton Dickinson Monoclonal Antibody Center) HLA-DR. After 1 h incubation, plates were washed and incubated for 1 h with 1 : 1000 dilutions of affinity-purified rabbit antimouse IgG. After washing, plates were incubated with 40,000 cpm of l~SI-protein A for 1 h, washed, and read on a gamma counter.
Two SCLC lines (H-209, H-146) were also grown and assayed similarly with recombinant leukocyte A interferon, with assays performed at 24, 48, 72, and 96 h after exposure to the interferon. Larger wells, containing 106 cells per well of SCLC line NCI-H446, were assayed on an indirect immunofluorescence assay with either PBS or 104 U/ml of leukocyte A interferon at 24, 48, and 72 h after incubation. Indirect immunofluorescence assays were performed with W6/32 and L-368 as previously described.
lmmunohistochemistry. Malignant human tissues and cultured ceils were obtained, formalin-fixed, embedded, cut, and stained as described (23) . Control and interferon-treated cells were cytocentrifuged onto glass slides and fixed for 10 min with acetone at 4°C. The slides were incubated at room temperature with either anti-HLA-A,B,C, anti-/3zm, anti-HLA-DR, or control antibodies, for 45 min. After rinsing the slides, the cells were exposed to biotin-labeled goat anti-mouse Ig for 30 rain. The slides were incubated in methanol H202 solution for 30 rain before the application of avidin-biotin-peroxidase complex (ABC), followed by diaminobenzidine-nickle chloride-H~O2 solution (24) . The smears were counterstained with methyl green. All slides were reviewed by three clinical pathologists (A. Gazdar, I. Linnoila, and S. Martin).
Results

SCLC Cultured Cell Lines Express Greatly
Reduced Amounts of Surface HLA or 132m Antigens. Six independent monoclonal antibodies specific for invariant determinants on the class I HLA-A,B,C and ~2m proteins were tested for binding to SCLC, NSCLC, and non-lung cancer lines. In protein A-radiobinding assays, high levels of binding were seen with the anti-HLA antibodies to NSCLC and non-lung cancer lines and approached saturation at 10 ~tg/ml antibody per 10 ~ target cells (Table I ). In contrast, no or greatly reduced binding was noted with the small cell lines, depending on the antibody used. A single exception was line NCI-H526, an SCLC line by morphology, which consistently had high expression of HLA antigenic determinants, approaching the NSCLC levels, with the three monoclonal antibodies used. A similar pattern of results was noted with the Assays were performed using a ~25I-protein A assay with commercial monoclonal antibodies at a concentration of 10 #g/ml. Results are the average of triplicate determinations (<20% variance between wells for any one test). The negative control was obtained by substituting a class-matched indifferent myeloma protein for the specific monoclonal antibody. Control radiobinding counts varied from 100 to 800 with the different antibodies. The numbers shown represent the cpm of the test well minus the cpm of the negative control. NT, not tested. * Monoclonal antibody assays using a rabbit anti-mouse IgG connecting antibody. monoclonal antibodies directed against ~2m, with a strong reaction to NSCLC noted with three different antibodies. The 11 SCLC lines tested, with the striking exception of NCI-H526, were negative with two of the anti-~2m antibodies and slightly positive with the other antibody, compared with a control IgG mouse myeloma protein. The ratios of NSCLC-to-SCLC binding of these antibodies was up to 100:1 with both HLA, A,B,C and/3~m monoclonal antibodies.
13 SCLC and four NSCLC cell lines were tested in indirect immunofluorescence assays for HLA-A,B,C and ~2nl expression, using live cells, to see if a subpopulation of SCLC expressed large amounts of the antigens. While >85% of the NSCLC ceils were brightly fluorescent, SCLC cells showed only faintly positive ceils. However, this positivity was present on the large majority of the cells. The median fluorescence of the SCLC cells was 10-100-fold less than the median fluorescence of the NSCLC cells with both HLA and/~2m monoclonal antibodies (data not shown). The only overlap in fluorescence intensity between SCLC and NSCLC with each antibody was again seen in line NCI-H526, which had much greater expression of HLA and/32m antigens than any other SCLC line.
Fresh SCLC Tumor Specimens Do Not Express Surface HLA-A,B,C. To determine whether the loss of class I histocompatibility antigens occurred while the tumor was in the patient or only after cell culture, we used tumor samples taken directly from SCLC and NSCLC patients for immunohistochemical staining with 9456-SA, a monocional antibody reactive to HLA-A,B,C. The staining of three SCLC samples revealed that uncultured SCLC cells had markedly reduced or undetectable HLA-A,B,C expression (data not shown). Similarly, staining of SCLC cells adjacent to bronchus or skin with a heteroantisera reactive to/32m showed that the surrounding nonmalignant cells were positively stained with the antisera, but that the SCLC cells were negative ( Fig. 1) .
SCLC Cells Synthesize Greatly Reduced Amounts of HLA-A,B,C and ~2m Proteins.
To determine whether the lack of expression on the cell surface of HLA-A,B,C and /3~m resulted from a deficiency of peptide chain synthesis, we performed immunoprecipitation with antibodies directed against HLA-A,B,C and /32m determinants. We used the monocional antibody W6/32 to precipitate the HLA-A,B,C antigen in 12 SCLC lines and five NSCLC lines (Fig. 2 ). The SCLC lines had a marked reduction in HLA-A,B,C protein immunoprecipitated compared with the NSCLC lines, with the exception again of NCI-H526. Densitometric analysis of the SCLC HLA protein bands showed that the median SCLC line synthesized 1/20th the amount of HLA protein compared with the median NSCLC line (Table II) . In the NSCLC lines, a 12,000 mol wt band was also noted, presumably arising from co-immunoprecipitated fl~m bound to the HLA-A,B,C molecule. This was not seen in any of the SCLC lines. This co-immunoprecipitation of fl2m has been previously described with W6/32 (25) .
To directly precipitate ~2m, we used an affinity-purified rabbit anti-human /3~m heteroantiserum (this serum behaved similarly to the monoclonal antibodies used in the radiobinding assays described above). Using the same 12 SCLC and five NSCLC lines as in the HLA immunoprecipitation, we found a marked reduction in the 12,000 tool wt/32m bands precipitated in SCLC compared with NSCLC (Fig. 3) . Densitometry analysis showed the median value of the SCLC t32m b a n d s to be 1 / 1 0 t h o f the m e d i a n N S C L C value ( T a b l e II). O f i n t e r e s t is the a b n o r m a l l y high m o l e c u l a r w e i g h t o f the 13~m b a n d seen in N C I -H 4 4 6 , a S C L C line (Fig. 3) . antigens was correlated with greatly reduced immunoprecipitable peptide chains, we next investigated class I MHC mRNA production. We analyzed RNA blots from 12 well-characterized human lung cancers with molecularly cloned HLA and /32m cDNA probes. The HLA cDNA probe used (psw) corresponds to an HLA-B locus alloantigen (19) , and detects a single RNA band of ~ 1,400 nucleotides. When NSCLC total cellular RNA was probed with psw, a single distinct band of 1.4 kilobase (kb) was seen (Fig. 4) . Of the 10 SCLC lines tested, several failed to give a positive signal, and most gave a faint positive signal only after prolonged exposure of the gel. Densitometric analysis indicated that the median density of the SCLC HLA mRNA binds was less than one-fifth that of the NSCLC values (Table II) . As a positive control, we used a B lymphoblastoid line (NCI-HI28 BL) derived from the same patient as the NCI-H128 SCLC line; it showed a strong, single, 1.4 kg HLA mRNA band.
SCLC Cells Contain Markedly Reduced Levels
The /3~m cDNA probe used detects a single RNA band of 620 nucleotides (20) . Using the same cell lines as in the psw assay, we found a 0.6 kb band in the B lymphoblastoid and lung adenocarcinoma lines (Fig. 5) . The 10 SCLC lines tested showed positive but reduced signals with median densitometric/~2m mRNA levels less than one fifth of the NSCLC values (Table II) . The SCLC line NCI-H526 was again the exception, with levels of HLA and/32m mRNA comparable to the NSCLC levels, correlating with its increased HLA and /32m protein synthesis. 
(B) NCI-N417 (SCLC-v); (C) NCI-H128 BL (immortalized lymphob|astoid line); (D) NC1-H 128 (SCLC); (E) NCI-H 146 (SCLC); (F) NCI-H69 (SCLC); (G) NCI-H23 (NSCLC).
FIGURE 5. Northern blot analysis of RNA prepared from fresh cell cultures. 10 #g of total cytoplasmic RNA was denatured and electrophoresed on a 1% agarose-formaldehyde gel. The /3~m probe was a human cDNA fragment that hybridizes to a single 0.6 kb RNA band.
Radioautography was performed with a 96 h exposure. (a) NCI-H 187 (SCLC); (b) NCI-H231 (SCLC); (c) NCI-H524 (SCLC-v); (d) NCI-N417 (SCLC-v); (e) NCI-H69 (SCLC); (f) NC1-H249 (SCLC); (g) NCI-H23 (NSCLC); (h) NCI-H125 (NSCLC); (i) NCI-H128 BL (B lymphoblastoid).
HLA and 132m Genes Are Present in SCLC. Because o f d e c r e a s e d m R N A p r o d u c t i o n we n e x t a s k e d if d e l e t i o n o
r r e a r r a n g e m e n t o f class I a n t i g e n genes h a d t a k e n place. W e a n a l y z e
d E c o R I -d i g e s t e d g e n o m i c D N A f r o m e i g h t wellc h a r a c t e r i z e d h u m a n l u n g c a n c e r cell lines with the H L A and/32m c D N A p r o b e s , using the S o u t h e r n n i t r o c e l l u l o s e t r a n s f e r m e t h o d (16). T h e p o l y m o r p h i c b a n d -
ing pattern detected by the psw probe in the SCLC lines was similar to the signals detected with the NSCLC and control cell line lanes (data not shown). The DNA banding pattern detected with the /32m probe was identical in the SCLC and NSCLC lines (data not shown).
Interferon Induces Increased Expression of Surface HLA-A,B,C and/32m Antigens in SCLC Cells.
Interferon has been shown to increase HLA and/32m expression in several systems (26, 27) . SCLC cells were incubated with interferon and the class I MHC antigen expression was monitored. Recombinant leukocyte A interferon increased the expression of HLA-A,B,C and/32m surface antigens in radiobinding (Fig. 6 ) and indirect immunofluorescence assays (Fig. 7) . Gamma interferon also increased /~2m expression 3-50-fold and increased HLA-A,B,C antigen 2-24-fold (Table III) . In contrast, interferon had no effect on HLA-DR expression, which remained low (data not shown). The expression of both antigens increased with increasing doses up to 104 U/ml of both gamma and recombinant leukocyte A interferons. The effect of both gamma and leukocyte A interferons in all assays was complete at 24 h and was not appreciably altered between 24 and 96 h. In addition both interferons also increased HLA-A,B,C and 132m expression on the several NSCLC lines and the B lymphoblastoid line tested. In indirect immunofluorescence assays with SCLC line NCI-H446, the number of antigen-positive cells increased; also, fluorescence increased >10-fold in both HLA-A,B,C and/32m assays after incubation with 104 U/ml of recombinant leukocyte A interferon, compared with treatment with the PBS control (Fig. 7) .
The SCLC line NCI-H69 was used for immunohistochemical staining with an anti-HLA monoclonal antibody before and after interferon treatment (data not shown). 6. Radiobinding assay using W6/32, a monoclonal antibody reactive to HLA-A,B,C, and L-368, a monoclonal antibody reactive to B~m, to determine expression of these antigens on two SCLC lines (NCI-H209 and NCI-H 146) after incubation with varying concentrations of recombinant leukocyte A interferon. Interferon was added in triplicate to wells of each line at concentrations of 0-104 U/ml. After 24 h, cells were fixed with glutaraldehyde and assayed with the monoclonal antibodies. Plates were sequentially incubated with an affinity-purified rabbit anti-mouse IgG antiserum and 125I-labeled protein A, and the wells were counted on a gamma counter. 
TABLE III
Induction of HLA-A,B,C and ~2m Antigens by Interferon in SCLC Cell Lines
Cell line
Fold induction of:
HLA-A,B,C /32m NCI-H60  4  17  NCI-H69  10  51  NCI-H 128  18  34  NCI-H 146  24  5  NCI-HI87  2  3  NCI-H209  14  12  NCI-H417  3  23 Assays were performed on SCLC cells incubated at I0 ~ cells per well in microtiter wells with 104 U/ml of gamma interferon for 48 h. Control wells with no interferon were prepared for each cell line. After 48 h, cells were washed with PBS and fixed to polyvinylchloride plates with 0.25% glutaraldehyde. The plates were reacted with 50 #1 of W6/32 (reactive with HLA-A,B,C) or L-368 (reactive with/32m). Both antibodies were at a concentration of 10 tzg/ml. The plates were washed, then serially incubated with affinity-purified rabbit anti-mouse lgG and ~2~I-labeled staphylococcal protein A. Counts were read on a gamma counter. Results represent the mean number of counts for each cell line after interferon incubation divided by the mean number of counts of the control wells.
interferon treatment but became markedly positive after 48 h exposure to 104 U/ml of gamma interferon incubation. In contrast, control immunoperoxidase staining with a monoclonal antibody reactive to HLA-DR remained negative after interferon incubation (data not shown). Including this report, three classes of human carcinomas have been shown to have frequent deficits of class I MHC antigen expression: germ cell cancers, neuroblastoma, and now, small-cell lung cancer. The recently described HLA-A,B,C deficiencies in neuroblastoma are particularly interesting since they extend the biochemical similarities noted between adrenergic neuroblastomas and SCLC. Both of these tumors produce L-dopa decarboxylase (8) , have similar patterns of reactivity to monoclonal antibodies developed in our laboratory (1 1, 29) , and have similar cell surface protein phenotypes (30) . The markedly reduced surface expression of class I MHC peptides in both cell types raises the question of whether other normal and malignant APUD cells lack HLA-A,B,C and ¢/2m expression. However, neuroblastoma cell lines produce/32m while displaying no detectable HLA-A,B,C antigen (2), whereas SCLC lines appear to have deficiencies of both HLA framework and/32m proteins (though the/32m deficiency may be less marked than the HLA-A,B,C loss). There is a reproducible spectrum in the degree of HLA-A,B,C deficiency in the SCLC lines with a roughly parallel decrease in internal 132m peptide. While small amounts of 132m proteins are translated in all SCLC cell lines, the absence of intracellular HLA-A,B,C protein may prevent 13em from getting to the cell surface, explaining the more striking deficiency of 132m protein by radiobinding assays. Alternatively, an altered form of internal/32m peptide, as seen in NCI-H446, may not be transported to the cell surface. SCLC is unique among human tumor lines in having deficiencies of expression of both class I chains: the germ cell tumors and occasional breast, colon, and lymphoma lines with class I MHC deficiencies all appear to lack only one of the two antigens. In the Daudi Burkitt's lymphoma line (31) , the inability to produce ~2m may be associated with major deletions on chromosome 15, where the/32m gene is located (31) . Karyotyping of multiple SCLC lines (10) has not shown any obvious abnormalities of chromosomes 15 or 6, where the human class I MHC genes are located.
The closest parallel to the loss of both HLA-A,B,C and/32m antigens in SCLC lines appears to be the F9 mouse teratocarcinoma line. This line has been shown to have an RNA transcription block of both class I MHC antigens (6) . Of interest, F9 cells have been shown to have a surface glycoprotein identified as the stagespecific embryonic antigen (SSEA) (32, 33) . SSEA is found in the early embryo and disappears at the same developmental stage that H-2 MHC antigens appear (34) . The majority of SCLC lines have a dominant carbohydrate antigen lacto-N-fucopentose III (LNFP3), which is identical to the determinant recognized by monoclonal antibodies made against SSEA (35) . However, using [35S]methioninelabeled SCLC cells, we have so far been unable to immunoprecipitate a protein with 534-F8, a monoclonal anti-SCLC antibody reactive to LNFP3 (35) . The F9 teratocarcinoma line has been shown to differentiate with retinoic acid treatment (36) , and differentiated clones were found to express H-2 and/3em antigens but to have lost SSEA expression (36) . In contrast, treatment of SCLC cells with recombinant leukocyte A interferon did not cause a reduction in their high reactivity to 534-F8 after induction of HLA-A,B,C and 132m peptide synthesis (data not shown).
Interferons have been found to augment expression of class I MHC antigen expression in melanoma cells (26) , and have been shown to induce mRNA for MHC antigens in human fibroblasts and lymphoblastoid cells (27) . The current experiments, however, represent the first reported example of interferons increasing the RNA transcription of class I MHC antigens that had been markedly diminished. There is a presumed role for interferon in increasing HLA expression, as part of the immune response of a virally infected host, for the elimination of HLA-matched infected cells. Increased HLA expression in SCLC might be expected to facilitate the destruction of cells bearing tumor-associated antigens.
With 25,000 cases of SCLC diagnosed in the United States every year, SCLC is the most common human malignancy associated with major deficiencies of class I antigens. As a tumor that can be grown in cell culture with high efficiency it is a valuable model for studies on human histocompatibility antigen expression. Our results also raise a basic clinical question. A growing body of literature (37) (38) (39) suggests that class II MHC antigens participate in the lysis of tumor cells by cytotoxic T lymphocytes. It has been suggested (40) that a lack of HLA-A,B,C may offer a growth advantage to tumors with weak expression of the molecules. Studies with melanoma line variants that were low in class I MHC expression (41) showed that these variants were more likely to metastasize from locally implanted mouse tumors than were lines high in MHC expression. In this context we note that SCLC is clinically characterized by aggressive growth and early metastasis. Since NSCLC (which requires different treatment than SCLC) expresses both HLA-A,B,C and ¢/2m antigens, these markers are of immediate diagnostic value in tumor typing. Administering interferon to SCLC patients after their tumor bulk had been reduced by chemotherapy and radiotherapy could be of value in delaying or preventing tumor recurrence.
The mechanism of decreased class I MHC mRNA transcription in SCLC cells is unknown, but may be comparable to the decrease in histocompability antigen transcription seen in rat cells after malignant transformation by the Ela region of adenovirus strain 12 (7) . The small-cell variant lines have been shown to have an amplification of the c-myc oncogene (12) which, like Ela, appears to have an establishment function in cell transformation (42) . Cell lines of neuroblastoma, the other non-germ cell tumor with consistent decreases in class I MHC antigen expression, also have amplification of a c-myc-related oncogene, N-myc (43) . In general, the SCLC lines with the greatest amplification of c-myc also had the lowest measurable levels of class I histocompatibility antigens. Of interest, NCI-H23, a lung adenocarcinoma line amplified for c-myc, had significantly lower amounts of HLA-A,B,C protein and mRNA than the other NSCLC lines tested. Decreased transcription of class I MHC message may be a common aspect of malignant transformation with the functional class of oncogenes that include, cmyc, N-myc, and E la.
Summary
We have found markedly deficient expression of the class I major histocompatibility antigens HLA-A,B,C and t32m on human small-cell lung cancer (SCLC) lines and fresh tumor samples. The deficit of HLA-A,B,C and/32-microglobulin (/~2m) antigen expression was demonstrated with both radiobinding assays and indirect immunofluorescence assays. Immunoprecipitation of metabolically labeled cells with antibodies to class I antigens showed most SCLC lines to have synthesized almost no /~2m and HLA-A,B,C proteins. Northern blot analysis, using human HLA-A,B, and/3zm cDNA probes, showed that almost all SCLC lines tested had markedly decreased amounts of HLA and/3~m mRNA, but both gene products could be induced with interferon treatment of SCLC lines. We conclude that human SCLC, in contrast to other lung cancer types, is characterized by greatly reduced transcription of HLA-A,B,C and /32m genes, which suggests the existence of a mechanism for evading the host immune response to the tumor and of an Ela-like product in this type of tumor cell.
